Cytokine therapy for hematological malignancies

International Journal of Hematology

Volumn 65, Issue 1, 1996, Pages 17-29

  Ezaki, Kohji ^a  

^a FUJITA HEALTH UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Cytokine; G CSF; GM CSF; Hematological malignancy; Interferon

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; CYTOKINE; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;

HEMATOLOGIC DISEASE; HUMAN; LEUKEMIA; PRIORITY JOURNAL; REVIEW;

EID: 0030561070     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0925-5710(96)00492-6     Document Type: Review

References (63)

1. [1] Metcalf D. Hematopoietic regulators: redundancy or subtlety? Blood 1993;82:3515-3523.
2. [2] Talpaz M, McCredie KB, Mavligit GM, Gutterman JU. Leukocyte interferon-induced myeloid cytoreduction in chronic myelogenous leukemia. Blood 1983;62:689-692.
3. [3] Talpaz M, Kantarjian HM, McCredie KB, Keating MJ, Trujillo J, Gutterman JU. Clinical investigation of human alpha interferon in chronic myelogenous leukemia. Blood 1987;69:1280-1288.
4. [4] Talpaz M, Kantarjian HM, McCredie KB, Trujillo JM, Keating MJ, Gutterman JU. Hematologic remission and cytogenetic improvement induced by recombinant human interferon alpha A in chronic myelogenous leukemia. N Engl J Med 1986;314:1065-1069.
5. [5] Ozer H, George SL, Schiffer CA et al. Prolonged subcutaneous administration of recombinant α2b interferon in patients with previously untreated Philadelphia chromosome-positive chronic-phase chronic myelogenous leukemia: effect on remission duration and survival: Cancer and Leukemia Group B Study 8583. Blood 1993;82:2975-2984.
6. [6] Morra E, Lazzarino M, Alimena G et al. The role of interferon in the treatment of chronic myelogenous leukemia: results and prospects. Leukemia Lymphoma 1992;6:305-315.
7. [7] Koyama S, Moriyama Y, Shibata A et al. Clinical investigation of natural interferon alpha (HLBI) in chronic myelogenous leukemia-A multi-institutional cooperative study in Japan. Jpn J Cancer Chemother 1988;15:2959-2966.
8. [8] Kantarjian HM, Deisseroth A, Kurzrock R, Etrov Z, Talpaz M. Chronic myelogenous leukemia: a concise update. Blood 1993;82:691-703.
9. [9] The Italian Cooperative Study Group on Chronic Myeloid Leukemia. Interferon α-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. N Engl J Med 1994;330:820-825.
10. [10] Hehlmann R, Heimpel H, Hasford J et al. Randomized comparison of interferon alpha with busulfan and hydroxyurea in chronic myelogenous leukemia. Blood 1994;84(Suppl 1):382a (# 1512).
11. [11] Allan ND, Shepherd PCA, Richards SM et al. Interferon-α prolongs survival for patients with CML in chronic phase: preliminary results of the UK MRC randomized multicenter trial. Blood 1994;84(Suppl 1):382a (# 1513).
12. [12] Ohnishi K, Ohno R, Tomonaga M et al. A randomized trial comparing interferon-α with busulfan for newly diagnosed chronic myelogenous leukemia in chronic phase. Blood 1995;86:906-916.
13. [13] Bergsagel DE, Messner H. The maintenance of busulfan-induced remission in chronic granulocytic leukemia with recombinant interferon α2b. Br J Cancer 1990;61:895-898.
14. [14] Giles FJ, Aitchison R, Syndercombe-Court D, Schey S, Newland AC. Recombinant alpha 2b interferon in combination with oral chemotherapy in late chronic phase chronic myeloid leukemia. Leukemia Lymphoma 1992;7:99-102.
15. [15] Kantarjian HM, Talpaz M, Keating MJ et al. Intensive chemotherapy induction followed by interferon-α maintenance in patients with Philadelphia chromosome-positive chronic myelogenous leukemia. Cancer 1991;68:1201-1207.
16. [16] Kantarjian HM, Keating MJ, Estey EH. Treatment of advanced stages of Philadelphia chromosome-positive chronic myelogenous leukemia with interferon-α and low-dose cytarabine. J Clin Oncol 1993;10:772-778.
17. [17] McGlave PB. Therapy of chronic myelogenous leukemia with related or unrelated donor bone marrow transplantation. Leukemia 1992;6:115-117.
18. [18] Nagao T. National registry of stem-cell transplantation in Japan. Transplant Now 1994;7:93-101.
19. [19] McGlave P, Bartsh G, Anasetti C et al. Unrelated donor marrow transplantation therapy for chronic myelogenous leukemia: initial experience of the National Marrow Donor Program. Blood 1993;81:543-550.
20. [20] Österborg A, Björkholm M, Björeman M et al. Natural interferon-α in combination with melphalan/prednisone versus melphalan/prednisone in the treatment of multiple myeloma stages II and III: a randomized study from the Myeloma Group of Central Sweden. Blood 1993;81:1428-1434.
21. [21] Cooper MR, Dear K, McIntyre OR et al. A randomized clinical trial comparing melphalan/prednisone with or without alpha 2b interferon in newly diagnosed multiple myeloma: A CALGB study. J Clin Oncol 1993;11:155-160.
22. [22] Oken MM, Kyle RA, Greipp PR, Kay NE, Tsiatis A, O'Connell MJ. Chemotherapy plus interferon (rIFNα2) in the treatment of multiple myeloma. Proc Am Soc Clin Oncol 1990;9:288 (# 1116).
23. [23] Ludwig H, Cohen AM, Huber H et al. Interferon with VMCP compared to VMCP for induction and IFN compared to control for remission maintenance in multiple myeloma. Proc Am Soc Clin Oncol 1994;13:408 (# 1393).
24. [24] Mandelli F, Avvisati G, Amadori S et al. Maintenance treatment with recombinant interferon α-2b in patients with multiple myeloma responding to conventional induction chemotherapy. N Engl J Med 1990;322:1430-1434.
25. [25] Salmon SE, Crowley JJ, Grogan TM, Finley P, Pugh RP, Barlogie B. Combination chemotherapy, glucocorticoids and interferon alpha in the treatment of multiple myeloma: A Southwest Oncology Group Study. J Clin Oncol 1994;12:2405-2414.
26. [26] Browman GP, Rubin S, Walker I et al. Interferon α-2b maintenance therapy prolongs progression-free and overall survival in plasma cell myeloma: results of a randomized trial. Proc Am Soc Clin Oncol 1994;13:408 (# 1391).
27. [27] The American Society of Clinical Oncology. American Society of Clinical Oncology recommendation for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. J Clin Oncol 1994;12:2471-2508.
28. [28] Masaoka T, Moriyama Y, Kato S et al. A randomized, placebo-controlled study of KRN8601 (recombinant human granulocyte colony-stimulating factor) in patients receiving allogeneic bone marrow transplantation. Jpn J Med 1990;3:233-239.
29. [29] Powles R, Smith C, Milan S. Human recombinant GM-CSF in allogeneic bone marrow transplantation for leukemia: double-blind, placebo controlled trial. Lancet 1990;336:1417-1420.
30. [30] Gupta P, Tiley C, Powles R et al. No increase in relapse in patients with myeloid leukaemias receiving rhGM-CSF after allogeneic bone marrow transplantation. Bone Marrow Transplant 1992;9:491-493.
31. [31] Kritz A, Crown JP, Motzer RJ et al. Beneficial impact of peripheral blood progenitor cells in patients with metastatic breast cancer treated with high-dose chemotherapy plus granulocyte-macrophage colony-stimulating factor. A randomized trial. Cancer 1993;71:2515-2521.
32. [32] Tepler I, Cannistra SA, Frei E III et al. Use of peripheral-blood progenitor cells abrogates the myelotoxicity of repetitive out-patient high-dose carboplatin and cyclophosphamide chemotherapy. J Clin Oncol 1993;11:1583-1591.
33. [33] Dreger P, Haferlach T, Eckstein V et al. G-CSF mobilized peripheral blood progenitor cells for allogeneic transplantation: safety, kinetics of mobilization, and composition of the graft. Br J Haematol 1994;87:609-613.
34. [34] Bensinger WI, Weaver CH, Appelbaum FR et al. Transplantation of allogeneic peripheral blood stem cells mobilized by recombinant granulocyte colony stimulating factor. Blood 1995;85:1655-1658.
35. [35] Gurney H, Dodwell D, Thatcher N et al. Escalating drug delivery in cancer chemotherapy: a review of concepts and practice Part 2. Ann Oncol 1993;4:103-115.
36. [36] Vellenga E, Yong DC, Wagner K, Wiper D, Ostapovicz D, Griffin JD. The effect of GM-CSF and G-CSF in promoting growth of clonogenic cells in acute myeloblastic leukemia. Blood 1987;69:1771-1776.
37. [37] Delwel R, Salem M, Pellens C et al. Growth regulation of human acute myeloid leukemia: effects of five recombinant hematopoietic factors in a serum-free culture system. Blood 1988;72:1944-1949.
38. [38] Lowenberg B, Touw IP. Hematopoietic growth factors and their receptors in acute leukemia. Blood 1993;81:281-292.
39. [39] Motoji T, Watanabe M, Uzumaki H et al. Granulocyte colony-stimulating factor receptors on acute myeloblastic leukemia cells and their relationship with the proliferative response to G-CSF in clonogenic assay. Br J Haematol 1991;77:54-59.
40. [40] Begley CG, Metcalf D, Nicola NA. Purified colony stimulating factors (G-CSF and GM-CSF) induce differentiation in human HL60 leukemic cells with suppression of clonogenicity. Int J Cancer 1987;39:99-105.
41. [41] Geissler K, Harrington M, Srivastave C, Leemhuis T, Tricot G, Broxmeyer HE. Effect of recombinant human colony stimulating factor (CSF) on human monocyte/ macrophage differentiation. J Immunol 1989;143:140-146.
42. [42] Toki H, Matsumoto S, Okabe K, Shimokawa T. Remission in hypoplastic acute myeloid leukaemia induced by granulocyte colony-stimulating factor. Lancet 1989;1:1389-1390.
43. [43] Yamasaki Y, Izumi Y, Sawada H, Fujita K. Probable in vivo induction of differentiation by recombinant human granulocyte colony stimulating factor in acute promyelocytic leukemia (APL). Br J Haematol 1991;78:579-580.
44. [44] Ohno R, Tomonaga M, Kobayashi T et al. Effect of granulocyte colony-stimulating factor after intensive induction therapy in relapsed or refractory acute leukemia. N Engl J Med 1990;323:871-877.
45. [45] Rowe JM, Anderson J, Mazza J et al. Phase III randomized placebo-controlled study of granulocyte-macrophage colony-stimulating factor in adult patients with acute myelogenous leukemia: a study of the Eastern Cooperative Oncology Group. Blood 1993:82(Suppl 1):329a (# 1299).
46. [46] Stone R, George S, Berg D, Paciucci P, Schiffer C. GM-CSF v. placebo during remission induction for patients ≥ 60 years old with de novo acute myeloid leukemia: CALGB study 8923. Proc Am Soc Clin Oncol 1994;13:304 (# 992).
47. [47] Witz F, Harousseau JL, Cahn JY et al. GM-CSF during and after remission induction treatment for elderly patients with acute myeloid leukemia. Blood 1994;84(Suppl 1):231a (# 908).
48. [48] Zittoun R, Mandelli F, de Witte T et al. Recombinant human granulocyte-macrophage colony-stimulating factor during induction treatment of acute myelogenous leukemia: a randomized trial from EORTC-GIMEMA Leukemia Cooperative Groups. Blood 1994;84(Suppl 1):231a (# 909).
49. [49] Dombret H, Yver A, Chastang C, Degos I, the Cooperative Study Group. Increased frequency of complete remission by lenograstim recombinant human granulocyte colony-stimulating factor administration after intensive induction chemotherapy in elderly patients with de novo acute myeloid leukemia: final results of a randomized multicenter double-blind. controlled study. Blood 1994;84(Suppl 1):231a (# 910).
50. [50] Tafuri A, Andreeff M. Kinetic rationale for cytokine-induced recruitment of myeloblastic leukemia followed by cycle-specific chemotherapy in vitro. Leukemia 1990;4:826-834.
51. [51] Cannistra S, Groshek P, Griffin J. Granulocyte-macrophage colony-stimulating factor enhances the cytotoxic effects of cytosine arabinoside in AML and in myeloid blast crisis phase of CML. Leukemia 1989;3:328-334.
52. [52] Santini V, Nooter K, Delwel R, Lowenberg B. Susceptibility of acute myeloid leukemia cells from clinically resistant and sensitive patients to daunomycin: assessment in vitro after stimulation with colony stimulating factors. Leuk Res 1990;14:377-380.
53. [53] Archimbaud E, Fenaux P, Reiffers J et al. Granulocyte-macrophage colony-stimulating factor in association to timed-sequential chemotherapy with mitoxantrone, etoposide, and cytosine arabinoside for refractory acute myelogenous leukemia. Leukemia 1993;7:372-377.
54. [54] Estey E, Thall P, Andreeff M et al. Use of G-CSF before, during, and after fludarabine + ara-C induction therapy of newly-diagnosed AML or MDS: comparison with fludarabine + ara-C without G-CSF. J Clin Oncol 1994;12:671-678.
55. [55] Bettelheim P, Valent P, Andreeff M et al. Recombinant human granulocyte-macrophage colony-stimulating factor in combination with standard induction chemotherapy in de novo acute myeloid leukemia. Blood 1991;77:700-711.
56. [56] Estey E, Thall PF, Kantarjian HM et al. Treatment of newly diagnosed acute myelogenous leukemia with granulocyte-macrophage colony-stimulating factor (GM-CSF) before and during continuous infusion high-dose ara-C + daunorubicin: comparison to patients treated without GM-CSF. Blood 1992;79:2246-2255.
57. [57] Ohno R, Naoe T, Kanamaru A et al. A double-blind controlled study of granulocyte colony-stimulating factor started two days before induction chemotherapy in refractory acute myeloid leukemia. Blood 1994;83:2086-2092.
58. [58] Büchner T, Hiddemann W, Wormann B et al. GM-CSF multiple course priming and long-term administration in newly diagnosed AML: hematologic and therapeutic effects. Blood 1994;84(Suppl 1):27a (# 95).
59. [59] Heil C, Chadid L, Hoelzer D et al. GM-CSF in a double-blind randomized, placebo controlled trial in therapy of adult patients with de novo acute myeloid leukemia. Leukemia 1995;9:3-9.
60. [60] Tsuzuki M, Ezaki K, Nomura T et al. G-CSF containing combination chemotherapy for AML: correlation between in vitro proliferative response of AML cells to G-CSF and clinical outcome. Jpn J Clin Hematol 1994;35:1065 (WS 5).
61. [61] Reuter C, der Landwehr UA, Salleyer E et al. Modulation of intracellular metabolism of cytosine arabinoside in acute myeloid leukemia by granulocyte-macrophage colony-stimulating factor. Leukemia 1994;8:217-225.
62. [62] Eguchi K, Sasaki S, Tamura T et al. Dose escalation study of recombinant human granulocyte colony-stimulating factor (KRN8601) in patients with advanced malignancy. Cancer Res 1989;49:5221-5224.
63. [63] Ogawa M, Masaoka T, Mizoguchi H, Takaku F, Nakashima M. A phase III study of KRN8601 (rh G-CSF) on neutropenia induced by chemotherapy for malignant lymphoma - a multi-institutional, placebo controlled, double blind comparative study. Jpn J Cancer Chemother 1990;17:365-373.